Term ends May 19, 2030 · High confidence
20-year base term ends May 19, 2030
Held by Immunocore Limited
Filed Apr 8, 2019 as application 16/378,481 · Granted Dec 31, 2019
Base term, 20 years from filing
Today
2010
2030
Clock starts
May 19, 2010
May 19, 2010
Term ends
May 19, 2030
May 19, 2030
Granted
Dec 31, 2019
Dec 31, 2019
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,130,721, to May 19, 2030. The term already ends on or before that date, so the cap shortened nothing.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 19, 2010, when application PCT/GB2010/000988, the earliest non-provisional in its chain, was filed (this one was filed Apr 8, 2019) | May 19, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,130,721) | resolves to May 19, 2030, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | May 19, 2030 | High confidence |
This family
| US 10,130,721 | In force Jul 2030 | Jul 2030 |
| Application 16/151,144 | Abandoned not computed | not computed |
| US 10,420,846 | In force May 2030 | May 2030 |
| US 10,576,162 | In force May 2030 | May 2030 |
| US 10,517,960 | this patent May 2030 | May 2030 |
| Application 17/929,682 | Pending not computed | not computed |
6 of 7 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 15, 2019 Reel 49756, frame 895 | Jakobsen, Bent Karsten; Vuidepot, Annelise Brigitte; Li, Yi | Immunocore Limited | Assignment of Assignor's Interest |
| Nov 6, 2020 Reel 54344, frame 218 | Immunocore Limited; Immunocore LLC; Immunocore Commercial LLC | Oxford Finance Luxembourg S.À R.L., Registered with the Luxembourg Commercial Register Under Number B243395, Acting in Respect of Its Compartment 1 | Security Interest |
| Nov 8, 2022 Reel 61899, frame 866 | Immunocore Limited | Biopharma Credit PLC | Patent Security Agreement |
| Nov 10, 2022 Reel 61916, frame 493 | Oxford Finance Luxembourg S.À R.L | Immunocore Limited; Immunocore LLC; Immunocore Commercial LLC | Release of Security Interest |
| Nov 10, 2022 reel/frame not recorded | Oxford Finance Luxembourg S.À R.L | Immunocore Limited | Release of Security Interest |
| Nov 10, 2022 reel/frame not recorded | Oxford Finance Luxembourg S.À R.L | Immunocore LLC | Release of Security Interest |
| Nov 10, 2022 reel/frame not recorded | Oxford Finance Luxembourg S.À R.L | Immunocore Commercial LLC | Release of Security Interest |
| Nov 11, 2024 Reel 69197, frame 672 | Biopharma Credit PLC | Immunocore Limited | Release of Security Interest |
| Sep 18, 2025 Reel 72896, frame 339 | Adaptimmune Limited | Immunocore Limited | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
May 2030
Term ends May 19, 2030. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,130,721, ends no earlier than this term, so it caps nothing.
Citations
7
later US patents cite this one
That is above the median of utility patents granted in 2019 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.